Systematic review of pharmacogenomics and adverse drug reactions in paediatric oncology patients.
Rachel ConyersSubalatha DevarajaDavid ElliottPublished in: Pediatric blood & cancer (2017)
Many paediatric patients with cancer experience significant chemotherapy side effects. Predisposition to drug reactions is governed by single nucleotide polymorphisms (SNPs). We performed a systematic review of the literature from 2006 through 2016. Outcomes of interest included patient characteristics, cancer type drug of interest, genes investigated, toxicity identified and genetic polymorphisms implicated. The primary toxicities studied were neurotoxicity cardiotoxicity, osteonecrosis, and thromboembolism and hypersensitivity reactions. The retrieved studies were grouped according to toxicity reported and SNP associations. This review highlights the discoveries to date in pharmacogenomics and paediatric oncology along with highlighting some of the important limitations in the area.
Keyphrases
- adverse drug
- emergency department
- systematic review
- intensive care unit
- genome wide
- drug induced
- end stage renal disease
- electronic health record
- palliative care
- oxidative stress
- newly diagnosed
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- meta analyses
- papillary thyroid
- prognostic factors
- case report
- type diabetes
- randomized controlled trial
- locally advanced
- adipose tissue
- young adults
- squamous cell carcinoma
- mass spectrometry
- atomic force microscopy
- single molecule
- high resolution
- genetic diversity